디지털 치료제(DTx) 시장 : 제공별(소프트웨어, 몰입형), 용도별(치료(당뇨병, 중추신경계 질환, 심혈관질환, 재활), 예방), 수익 모델별(구독, 기업), 판매 채널별(B2B, B2C), 최종사용자별(병원, 보험자, 고용주) - 세계 예측(-2031년)

The global digital therapeutics market is projected to reach USD 35.37 billion by 2031 from USD 10.95 billion in 2026, at a CAGR of 26.4% from 2026 to 2031. The growth of the digital therapeutics market is being driven by the increasing prevalence of chronic diseases, rising demand for personalized and remote patient care, and the growing focus on improving clinical outcomes while reducing healthcare costs. Healthcare providers, payers, and employers are increasingly adopting evidence-based digital therapeutics to prevent, manage, and treat conditions such as diabetes, obesity, cardiovascular diseases, musculoskeletal disorders, insomnia, and mental health disorders through clinically validated software interventions.

Furthermore, regulatory and reimbursement support for digital health solutions continues to strengthen. In March 2025, the European Health Data Space (EHDS) Regulation entered into force, establishing a harmonized framework for the secure exchange and secondary use of electronic health data across the European Union, which is expected to facilitate the integration and scalability of digital therapeutics. In addition, continued advances in artificial intelligence (AI), remote patient monitoring, wearable technologies, and interoperable digital health infrastructure are enhancing the personalization, accessibility, and effectiveness of digital therapeutics while supporting value-based healthcare delivery. However, market growth may be constrained by fragmented reimbursement policies across countries, evolving regulatory requirements, concerns regarding data privacy and cybersecurity, limited awareness among healthcare professionals, and the need for robust clinical and real-world evidence to demonstrate long-term therapeutic and economic value.

"In 2025, the hospitals segment accounted for the largest share of the digital therapeutics market, by end user."

By end user, hospitals accounted for the largest share of the digital therapeutics market in 2025. Their leading position is driven by the increasing integration of digital therapeutics into multidisciplinary care pathways for chronic disease management, mental health, rehabilitation, and post-acute care. Hospitals are adopting these solutions to complement conventional therapies, improve patient engagement, support continuous remote monitoring, and enhance treatment adherence beyond inpatient settings. The growing emphasis on value-based care, reducing hospital readmissions, and delivering personalized, data-driven interventions has further accelerated the deployment of digital therapeutics across hospital networks. In addition, the availability of integrated digital health infrastructure, established clinical workflows, and stronger collaboration with technology developers and healthcare providers has enabled hospitals to effectively implement evidence-based digital therapeutic solutions at scale. As healthcare systems continue to prioritize connected care models and long-term disease management, hospitals have maintained their position as the largest end-user segment in the digital therapeutics market.

"The B2C segment, by sales channel, is expected to register the fastest growth during the forecast period."

By sales channel, the B2C (business-to-consumer) segment is expected to be the fastest-growing segment in the digital therapeutics market during the forecast period. This growth is driven by increasing consumer awareness of digital health solutions, rising demand for convenient self-management tools, and growing acceptance of preventive and wellness-focused care. Consumers are increasingly adopting digital therapeutics through mobile applications and connected devices to manage conditions such as obesity, sleep disorders, stress, anxiety, diabetes, and other lifestyle-related diseases without relying solely on traditional healthcare settings. The rapid expansion of smartphone penetration, wearable health technologies, and subscription-based digital health platforms has made these solutions more accessible and affordable for a broader population. Additionally, advancements in artificial intelligence, personalized behavioral coaching, and real-time health insights are improving user engagement and long-term adherence, while direct-to-consumer marketing strategies and expanding digital distribution channels are further accelerating the adoption of B2C digital therapeutics throughout the forecast period.

"Asia Pacific to witness the highest growth rate during the forecast period."

The Asia Pacific region is projected to register the highest growth rate in the digital therapeutics market during the forecast period. This growth is driven by the rising prevalence of chronic diseases, rapid healthcare digitalization, increasing smartphone adoption, and supportive government initiatives promoting digital health infrastructure across the region. Countries such as China, Japan, India, South Korea, Singapore, and Australia are expanding investments in telehealth, remote patient monitoring, artificial intelligence (AI)-enabled healthcare, and digital disease management to improve healthcare accessibility and address the growing burden of diabetes, cardiovascular diseases, obesity, and mental health disorders. Furthermore, the increasing presence of digital health startups, expanding collaborations between healthcare providers and technology companies, and growing reimbursement support for digital health solutions are accelerating the adoption of digital therapeutics across the region. Recent industry developments further reinforce this momentum; in February 2024, TruDoc Healthcare acquired Wellthy Therapeutics, one of Asia's leading digital therapeutics companies, to strengthen its digital healthcare capabilities across the GCC region while expanding into India, combining Wellthy's clinically validated digital therapeutics platform with TruDoc's virtual primary care and remote healthcare services. This acquisition highlights the increasing strategic investments in digital therapeutics and reinforces Asia Pacific's position as a key hub for innovation and commercialization in digital health.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
• By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
• By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, and Latin America: 2%

Key Players in the Digital Therapeutics Market

The key players functioning in the digital therapeutics market include Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), and Sword Health, Inc. (Portugal).

Research Coverage:

This research report categorizes the digital therapeutics market by offering (software/platforms, therapeutic programs, immersive & interface-based therapeutics), product type (prescription digital therapeutics, non-prescription digital therapeutics), application (treatment & care-related applications, preventive applications), revenue model (subscription-based model, licensing (enterprise/SAAS) model, outcome-/value-based model), sales channel (B2B sales channel, B2C sales channel), end user (healthcare provider, payers, employers, patients/individuals, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies (contracts, partnerships, agreements, product & service launches, mergers, and acquisitions), and recent developments associated with the digital therapeutics market. Competitive analysis of upcoming startups in the digital therapeutics market ecosystem is covered in this report.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (rising prevalence of chronic and behavioral health conditions, shift toward value-based and patient-centered care, expansion of smartphone adoption and digital health infrastructure, growing clinical evidence and regulatory recognition), restraints (limited reimbursement and inconsistent payment pathways, regulatory complexity and evolving approval frameworks), opportunities (expansion into new therapeutic areas, integration with AI and personalized medicine, increasing partnerships with pharmaceutical and healthcare organizations), and challenges (sustaining long-term patient engagement and adherence, demonstrating long-term clinical and economic value) influencing the growth of the digital therapeutics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the digital therapeutics market.
• Market Development: Comprehensive information on the lucrative emerging markets, offering, product type, application, revenue model, sales channel, end user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the digital therapeutics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the digital therapeutics market like Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), Sword Health, Inc. (Portugal).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
• 3.2 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE & COUNTRY
• 3.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising prevalence of chronic and behavioral health conditions
    • 4.2.1.2 Shift toward value-based and patient-centered care
    • 4.2.1.3 Expansion of smartphone adoption and digital health infrastructure
    • 4.2.1.4 Growing clinical evidence and regulatory recognition
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Limited reimbursement and inconsistent payment pathways
    • 4.2.2.2 Regulatory complexity and evolving approval frameworks
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion into new therapeutic areas
    • 4.2.3.2 Integration with AI and personalized medicine
    • 4.2.3.3 Increasing partnerships with pharmaceutical and healthcare organizations
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Sustaining long-term patient engagement and adherence
    • 4.2.4.2 Demonstrating long-term clinical and economic value
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 THREAT OF NEW ENTRANTS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.3.2 DATA INPUTS & TECHNOLOGY INFRASTRUCTURE
  • 5.3.3 PLATFORM DEVELOPMENT & DEPLOYMENT
  • 5.3.4 DISTRIBUTION
  • 5.3.5 MARKETING & SALES
  • 5.3.6 POST-SALES SERVICES
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY OFFERING (2025)
  • 5.5.2 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY REGION (2025)
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 CASE STUDY ANALYSIS
• 5.10 IMPACT OF 2025 US TARIFFS ON DIGITAL THERAPEUTICS MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRY/REGION
    • 5.10.4.1 US
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRY
    • 5.10.5.1 Healthcare providers
    • 5.10.5.2 Payers
    • 5.10.5.3 Employers
    • 5.10.5.4 Patients/Individuals
    • 5.10.5.5 Other end users

6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 SOFTWARE AS A MEDICAL DEVICE (SAMD)
  • 6.1.2 MOBILE HEALTH (MHEALTH) APPLICATIONS
  • 6.1.3 ARTIFICIAL INTELLIGENCE (AI) & MACHINE LEARNING (ML)
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 REMOTE PATIENT MONITORING (RPM)
  • 6.2.2 INTERNET OF MEDICAL THINGS (IOMT)
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 ELECTRONIC HEALTH RECORDS (EHR/EMR)
  • 6.3.2 DIGITAL DIAGNOSTICS
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 PATENT PUBLICATION TRENDS FOR DIGITAL THERAPEUTICS MARKET
  • 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 AI-ENABLED PERSONALIZED THERAPEUTICS & CLINICAL DECISION SUPPORT
  • 6.6.2 CONTINUOUS REMOTE CARE & DIGITAL HEALTH ECOSYSTEMS
  • 6.6.3 DIGITAL BIOMARKER-DRIVEN PREVENTIVE & PRECISION CARE
• 6.7 IMPACT OF AI/GEN AI ON DIGITAL THERAPEUTICS MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL THERAPEUTICS MARKET
  • 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
    • 6.7.3.1 AI technologies in digital therapeutics
  • 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
    • 6.7.4.1 Digital health & telehealth market
    • 6.7.4.2 Remote patient monitoring (RPM) market
    • 6.7.4.3 Electronic health records (EHR/EMR) market
  • 6.7.5 USER READINESS & IMPACT ASSESSMENT
    • 6.7.5.1 User readiness
      • 6.7.5.1.1 User A: Healthcare providers
      • 6.7.5.1.2 User B: Payers
    • 6.7.5.2 Impact assessment
      • 6.7.5.2.1 User A: Healthcare providers
        • 6.7.5.2.1.1 Implementation
        • 6.7.5.2.1.2 Impact
      • 6.7.5.2.2 User B: Payers
        • 6.7.5.2.2.1 Implementation
        • 6.7.5.2.2.2 Impact

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Latin America
    • 7.1.2.5 Middle East & Africa
  • 7.1.3 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 INTRODUCTION
• 8.2 DECISION-MAKING PROCESS
• 8.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.3.2 BUYING CRITERIA
• 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.5.1 UNMET NEEDS
  • 8.5.2 END-USER EXPECTATIONS
• 8.6 MARKET PROFITABILITY

9 DIGITAL THERAPEUTICS MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 SOFTWARE/PLATFORMS
  • 9.2.1 AI-DRIVEN PLATFORM ARCHITECTURES AND EXPANDING REGULATORY PATHWAYS TO DRIVE MARKET EXPANSION
• 9.3 THERAPEUTIC PROGRAMS
  • 9.3.1 EXPANDING FDA CLEARANCES ACROSS NEW INDICATIONS AND MATURING REIMBURSEMENT CODES TO DRIVE PROGRAM ADOPTION
• 9.4 IMMERSIVE & INTERFACE-BASED THERAPEUTICS
  • 9.4.1 GROWING CLINICAL EVIDENCE AND NEW REIMBURSEMENT CODES FOR VR-DELIVERED CARE TO DRIVE SEGMENT GROWTH

10 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE

• 10.1 INTRODUCTION
• 10.2 PRESCRIPTION DIGITAL THERAPEUTICS
  • 10.2.1 REGULATORY APPROVALS AND GROWING CLINICAL VALIDATION TO ACCELERATE ADOPTION OF PRESCRIPTION DIGITAL THERAPEUTICS
• 10.3 NON-PRESCRIPTION DIGITAL THERAPEUTICS
  • 10.3.1 INCREASING CONSUMER ACCESSIBILITY AND DIGITAL HEALTH ADOPTION TO ACCELERATE GROWTH OF NON-PRESCRIPTION DIGITAL THERAPEUTICS

11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 TREATMENT & CARE-RELATED APPLICATIONS
  • 11.2.1 DIABETES
    • 11.2.1.1 Rising global diabetes burden and connected digital care to accelerate adoption of digital therapeutics
  • 11.2.2 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
    • 11.2.2.1 Rising mental health burden and AI-enabled behavioral care to accelerate adoption of digital therapeutics for CNS disorders
  • 11.2.3 SMOKING CESSATION
    • 11.2.3.1 Increasing tobacco control initiatives and behavioral interventions to boost adoption
  • 11.2.4 CHRONIC RESPIRATORY DISEASES
    • 11.2.4.1 Rising burden of chronic respiratory conditions and remote disease management to fuel growth
  • 11.2.5 MUSCULOSKELETAL DISORDERS
    • 11.2.5.1 Rising burden of musculoskeletal conditions and AI-enabled rehabilitation to support market growth
  • 11.2.6 CARDIOVASCULAR DISORDERS
    • 11.2.6.1 Growing cardiovascular disease burden and remote cardiac care to contribute to market growth
  • 11.2.7 MEDICATION ADHERENCE
    • 11.2.7.1 Growing need to improve treatment compliance and long-term outcomes to drive growth
  • 11.2.8 SLEEP DISORDERS
    • 11.2.8.1 Rising prevalence of sleep disorders and connected sleep care to accelerate adoption of digital therapeutics
  • 11.2.9 REHABILITATION & PATIENT CARE
    • 11.2.9.1 Digital rehabilitation platforms to transform recovery beyond traditional clinical settings
  • 11.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
    • 11.2.10.1 Digital therapeutics to expand access to evidence-based addiction treatment and long-term recovery support
  • 11.2.11 OTHER TREATMENT & CARE-RELATED APPLICATIONS
• 11.3 PREVENTIVE APPLICATIONS
  • 11.3.1 PREDIABETES
    • 11.3.1.1 Early risk identification and lifestyle intervention to drive adoption of digital therapeutics for prediabetes
  • 11.3.2 OBESITY & WEIGHT MANAGEMENT
    • 11.3.2.1 Digital therapeutics to complement GLP-1 therapies and enable sustainable weight management
  • 11.3.3 NUTRITION & LIFESTYLE MANAGEMENT
    • 11.3.3.1 Personalized nutrition and lifestyle coaching to expand role of digital therapeutics in preventive healthcare
  • 11.3.4 OTHER PREVENTIVE APPLICATIONS

12 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL

• 12.1 INTRODUCTION
• 12.2 SUBSCRIPTION-BASED MODELS
  • 12.2.1 CONTINUOUS CARE DELIVERY AND RECURRING PATIENT ENGAGEMENT TO STRENGTHEN ADOPTION
• 12.3 LICENSING (ENTERPRISE/SAAS) MODELS
  • 12.3.1 ENTERPRISE ADOPTION AND SCALABLE CLOUD DEPLOYMENTS TO DRIVE GROWTH OF LICENSING (ENTERPRISE/SAAS) MODELS
• 12.4 OUTCOME-/VALUE-BASED MODELS
  • 12.4.1 GROWING SHIFT TOWARD PERFORMANCE-BASED REIMBURSEMENT TO DRIVE ADOPTION OF OUTCOME-/VALUE-BASED MODELS

13 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL

• 13.1 INTRODUCTION
• 13.2 B2B SALES CHANNELS
  • 13.2.1 HEALTHCARE ECOSYSTEM PARTNERSHIPS AND REIMBURSEMENT EXPANSION TO DRIVE B2B LEADERSHIP IN DIGITAL THERAPEUTICS
• 13.3 B2C SALES CHANNELS
  • 13.3.1 CONSUMER-CENTRIC DIGITAL HEALTH ADOPTION AND PREVENTIVE CARE TRENDS TO ACCELERATE B2C GROWTH

14 DIGITAL THERAPEUTICS MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 HEALTHCARE PROVIDERS
  • 14.2.1 HOSPITALS
    • 14.2.1.1 Expanding digital care delivery to drive hospital adoption of digital therapeutics
  • 14.2.2 SPECIALTY CLINICS
    • 14.2.2.1 Condition-specific care delivery to accelerate digital therapeutics adoption in specialty clinics
  • 14.2.3 DIAGNOSTIC & REHABILITATION CENTERS
    • 14.2.3.1 Digital rehabilitation and outcome-focused care to drive adoption in diagnostic & rehabilitation centers
  • 14.2.4 OTHER HEALTHCARE PROVIDERS
• 14.3 HEALTHCARE PAYERS
  • 14.3.1 PUBLIC PAYERS
    • 14.3.1.1 Government-led digital health programs to expand role of digital therapeutics in public healthcare
  • 14.3.2 PRIVATE PAYERS
    • 14.3.2.1 Outcome-based insurance models and employer health strategies to boost digital therapeutics adoption among private payers
• 14.4 EMPLOYERS
  • 14.4.1 GROWING EMPHASIS ON PREVENTIVE HEALTHCARE AND VALUE-BASED EMPLOYEE BENEFITS TO ACCELERATE ADOPTION ACROSS EMPLOYER SEGMENT
• 14.5 PATIENTS/INDIVIDUALS
  • 14.5.1 INCREASING PREFERENCE FOR SELF-MANAGED AND PREVENTIVE HEALTHCARE TO DRIVE ADOPTION IN SEGMENT
• 14.6 OTHER END USERS

15 DIGITAL THERAPEUTICS MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 15.2.2 US
    • 15.2.2.1 Expanding reimbursement, AI-powered care, and chronic disease management to drive digital therapeutics adoption
  • 15.2.3 CANADA
    • 15.2.3.1 Digital health expansion and public healthcare innovation to support digital therapeutics adoption
• 15.3 EUROPE
  • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 15.3.2 GERMANY
    • 15.3.2.1 Strong digital health ecosystem and favorable reimbursement to drive digital therapeutics adoption
  • 15.3.3 FRANCE
    • 15.3.3.1 Digital therapeutics access and reimbursement pathway development to boost market expansion
  • 15.3.4 UK
    • 15.3.4.1 NHS digital transformation and strong regulatory support to accelerate adoption
  • 15.3.5 ITALY
    • 15.3.5.1 Healthcare digitalization and chronic disease burden to create growth opportunities for digital therapeutics
  • 15.3.6 SPAIN
    • 15.3.6.1 Healthcare digitalization and telehealth expansion to drive digital therapeutics adoption
  • 15.3.7 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 15.4.2 CHINA
    • 15.4.2.1 Software-driven therapeutics to gain regulatory momentum amid government digital health push
  • 15.4.3 JAPAN
    • 15.4.3.1 Demographic pressures and regulatory reform to drive cautious digital therapeutics adoption
  • 15.4.4 INDIA
    • 15.4.4.1 Regulatory formalization and selective capital deployment to shape early-stage growth
  • 15.4.5 AUSTRALIA
    • 15.4.5.1 Strong digital health ecosystem and telehealth adoption to drive digital therapeutics growth
  • 15.4.6 SOUTH KOREA
    • 15.4.6.1 Government digital health initiatives and AI innovation to accelerate digital therapeutics adoption
  • 15.4.7 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 15.5.2 BRAZIL
    • 15.5.2.1 Universal healthcare expansion and digital health innovation to drive digital therapeutics demand
  • 15.5.3 MEXICO
    • 15.5.3.1 Growing public health needs and expanding digital access to support market growth
  • 15.5.4 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST & AFRICA
  • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 15.6.2 GCC COUNTRIES
    • 15.6.2.1 National digital health guidance to accelerate software-based therapeutic adoption
    • 15.6.2.2 Saudi Arabia
      • 15.6.2.2.1 Vision 2030 digital health guidance to establish formal pathway for software-based therapeutics
    • 15.6.2.3 UAE
      • 15.6.2.3.1 Digital transformation and healthcare innovation to support digital therapeutics growth
    • 15.6.2.4 Rest of Gcc Countries
  • 15.6.3 SOUTH AFRICA
    • 15.6.3.1 Digital health expansion and high disease burden to create opportunities for digital therapeutics
  • 15.6.4 REST OF MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

• 16.1 OVERVIEW
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET
• 16.3 REVENUE ANALYSIS, 2021-2025
• 16.4 MARKET SHARE ANALYSIS, 2025
• 16.5 BRAND/PRODUCT COMPARISON
• 16.6 COMPANY VALUATION & FINANCIAL METRICS
  • 16.6.1 FINANCIAL METRICS
  • 16.6.2 COMPANY VALUATION
• 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 16.7.1 STARS
  • 16.7.2 EMERGING LEADERS
  • 16.7.3 PERVASIVE PLAYERS
  • 16.7.4 PARTICIPANTS
  • 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 16.7.5.1 Company footprint
    • 16.7.5.2 Region footprint
    • 16.7.5.3 Offering footprint
    • 16.7.5.4 Application footprint
    • 16.7.5.5 Revenue model footprint
    • 16.7.5.6 End-user footprint
• 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 16.8.1 PROGRESSIVE COMPANIES
  • 16.8.2 RESPONSIVE COMPANIES
  • 16.8.3 DYNAMIC COMPANIES
  • 16.8.4 STARTING BLOCKS
  • 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 16.8.5.1 Detailed list of key startups/SMEs
    • 16.8.5.2 Competitive benchmarking of startups/SMEs
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 16.9.2 DEALS
  • 16.9.3 OTHER DEVELOPMENTS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 TELADOC HEALTH, INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products & services offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product launches & enhancements
      • 17.1.1.3.2 Deals
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Right to win
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 NOOM, INC.
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products & services offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches & enhancements
      • 17.1.2.3.2 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Right to win
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 HINGE HEALTH, INC.
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products & services offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product launches & enhancements
      • 17.1.3.3.2 Deals
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Right to win
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses & competitive threats
  • 17.1.4 OMADA HEALTH INC.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products & services offered
    • 17.1.4.3 Recent Developments
      • 17.1.4.3.1 Product Launches & Enhancements
      • 17.1.4.3.2 Deals
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Right to win
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 DARIOHEALTH CORP.
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products & services offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Product launches & enhancements
      • 17.1.5.3.2 Deals
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Right to win
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses & competitive threats
  • 17.1.6 SWORD HEALTH, INC.
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products & services offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Product launches & enhancements
      • 17.1.6.3.2 Deals
  • 17.1.7 RESMED
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products & services offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Deals
  • 17.1.8 VIRTA HEALTH CORP.
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products & services offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Product launches & enhancements
      • 17.1.8.3.2 Deals
  • 17.1.9 WELLDOC, INC.
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products & services offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product launches & enhancements
      • 17.1.9.3.2 Deals
  • 17.1.10 CLICK THERAPEUTICS, INC.
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products & services offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Product launches & enhancements
      • 17.1.10.3.2 Deals
      • 17.1.10.3.3 Other developments
  • 17.1.11 SIDEKICK HEALTH
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products & services offered
    • 17.1.11.3 Recent developments
      • 17.1.11.3.1 Product launches & enhancements
      • 17.1.11.3.2 Deals
  • 17.1.12 AKILI, INC.
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products & services offered
  • 17.1.13 APPLIEDVR, INC.
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products & services offered
    • 17.1.13.3 Recent developments
      • 17.1.13.3.1 Deals
  • 17.1.14 WELLTHY THERAPEUTICS PVT. LTD.
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products & services offered
  • 17.1.15 HEADSPACE INC.
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products & services offered
      • 17.1.15.2.1 Product launches & enhancements
  • 17.1.16 LARK TECHNOLOGIES, INC.
    • 17.1.16.1 Business overview
    • 17.1.16.2 Products & services offered
  • 17.1.17 XRHEALTH
    • 17.1.17.1 Business overview
    • 17.1.17.2 Products & services offered
    • 17.1.17.3 Recent developments
      • 17.1.17.3.1 Product launches
      • 17.1.17.3.2 Deals
  • 17.1.18 AMALGAM RX, INC.
    • 17.1.18.1 Business overview
    • 17.1.18.2 Products & services offered
    • 17.1.18.3 Recent developments
      • 17.1.18.3.1 Deals
  • 17.1.19 APTAR DIGITAL HEALTH
    • 17.1.19.1 Business overview
    • 17.1.19.2 Products & services offered
    • 17.1.19.3 Recent developments
      • 17.1.19.3.1 Deals
  • 17.1.20 CANARY HEALTH
    • 17.1.20.1 Business overview
    • 17.1.20.2 Products & services offered
    • 17.1.20.3 Recent developments
      • 17.1.20.3.1 Deals
• 17.2 START-UP/SME PLAYERS
  • 17.2.1 FREESPIRA
  • 17.2.2 MINDABLE HEALTH GMBH
  • 17.2.3 GET.ON INSTITUT FUR ONLINE GESUNDHEITSTRAININGS GMBH
  • 17.2.4 COGNIFIT INC.
  • 17.2.5 2MORROW INC.

18 RESEARCH METHODOLOGY

• 18.1 RESEARCH APPROACH
  • 18.1.1 SECONDARY RESEARCH
    • 18.1.1.1 Key data from secondary sources
  • 18.1.2 PRIMARY RESEARCH
    • 18.1.2.1 Primary sources
    • 18.1.2.2 Key data from primary sources
    • 18.1.2.3 Breakdown of primaries
    • 18.1.2.4 Insights from primary experts
• 18.2 RESEARCH METHODOLOGY DESIGN
• 18.3 MARKET SIZE ESTIMATION
• 18.4 DATA TRIANGULATION
• 18.5 MARKET SHARE ESTIMATION
• 18.6 STUDY ASSUMPTIONS
• 18.7 RESEARCH LIMITATIONS
  • 18.7.1 METHODOLOGY-RELATED LIMITATIONS
• 18.8 RISK ASSESSMENT

19 APPENDIX

• 19.1 DISCUSSION GUIDE
• 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 19.3 CUSTOMIZATION OPTIONS
• 19.4 RELATED REPORTS
• 19.5 AUTHOR DETAILS